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ISG15 is a ubiquitin-like modifier that also functions extracellularly, signaling through the LFA-1 integrin to
promote interferon (IFN)-g release from natural killer (NK) and T cells. The signals that lead to the production
of extracellular ISG15 and the relationship between its two core functions remain unclear. We show that both
epithelial cells and lymphocytes can secrete ISG15, which then signals in either an autocrine or paracrine
manner to LFA-1-expressing cells. Microbial pathogens and Toll-like receptor (TLR) agonists result in both
IFN-b-dependent and -independent secretion of ISG15, and residues required for ISG15 secretion are
mapped. Intracellular ISGylation inhibits secretion, and viral effector proteins, influenza B NS1, and viral
de-ISGylases, including SARS-CoV-2 PLpro, have opposing effects on secretion of ISG15. These results
establish extracellular ISG15 as a cytokine-like protein that bridges early innate and IFN-g-dependent im-
mune responses, and indicate that pathogens have evolved to differentially inhibit the intracellular and extra-
cellular functions of ISG15.
INTRODUCTION
ISG15 is a ubiquitin-like protein (Ubl) consisting of two ubiquitin-
like domains connected by a short linker (Narasimhan et al.,
2005). Expression of ISG15 is induced by type I interferon (IFN-
a/b) signaling (Farrell et al., 1979), although other innate immune
activators can lead to expression of ISG15 (Ashley et al., 2019;
Lertsooksawat et al., 2019; Radoshevich et al., 2015). ISG15
was the first Ubl modifier to be described (Haas et al., 1987;
Loeb and Haas, 1992), and ISGylation of host and/or pathogen
proteins has been best characterized as an antiviral defense
mechanism. Viruses that are inhibited by ISGylation include influ-
enza A, Ebola, hepatitis B and C, HIV, human papillomavirus
(HPV), vaccinia, West Nile, and Zika (Morales and Lenschow,
2013). Consistent with its antiviral function, many viruses,
including Nairoviruses, coronaviruses, and foot and mouth dis-
ease virus (FMDV), have devised mechanisms for inhibiting or
reversing ISGylation, including by expression of ISG15 deconju-
gating enzymes (Frias-Staheli et al., 2007; Lindner et al., 2007;
Mielech et al., 2014; Swatek et al., 2018; Dzimianski et al.,
2019a), while the influenza B virus NS1 (NS1B) proteins bind non-
covalently to ISG15 and sequester ISGylated proteins (Zhao
et al., 2016).
Hundreds of cellular and viral proteins are ISGylated in type I
IFN-stimulated cells (Zhao et al., 2005). The basis of the extreme
range of ISGylation substrates is that Herc5, the major E3
enzyme for ISG15, is ribosome-associated and broadly ISGy-
lates proteins co-translationally in a near-stochastic manner
(Durfee et al., 2010). Like ISG15, the E1, E2, and E3 enzymes
for ISG15, Ube1L/Uba7 (Yuan and Krug, 2001), Ube2L6 (Kim
et al., 2004; Zhao et al., 2004), and Herc5 (mouse Herc6) (Dastur
et al., 2006; Oudshoorn et al., 2012; Ketscher et al., 2012) are all
induced at the transcriptional level by type I IFN signaling, as is
the major deconjugating enzyme for ISG15, Usp18 (mouse
Ubp43) (Malakhov et al., 2002). The biochemical effects of ISGy-
lation on both viral and cellular proteins and the basis of its anti-
viral effects remain important areas of investigation. We previ-
ously proposed that viral proteins, rather than cellular proteins,
are likely to be the key biologically relevant targets of ISGylation,
and that oligomeric viral structural proteins may be particularly
sensitive to inactivation by ISGylation (Durfee et al., 2010). Evi-
dence for this was recently provided for influenza A virus, where
a relatively low level of ISGylation of the viral nucleocapsid pro-
tein (NP) had a dominant-negative effect on the ability of the
complex to package viral RNAs (Zhao et al., 2016).
Early publications indicated that ISG15 had a non-canonical
function as an extracellular signaling molecule, stimulating the
release of IFN-g from lymphocytes (D’Cunha et al., 1996; Recht
et al., 1991). A confirmation of the relevance of this finding came
with the discovery of ISG15-deficient patients who developed
mycobacterial infections after receiving the live-attenuated Ba-
cillus-Calmette-Guérin (BCG) tuberculosis vaccine (Bogunovic
et al., 2012). All previously identified patients who were classified
as ‘‘Mendelian susceptibility to mycobacterial disease’’ (MSMD)
patients were deficient in either producing or responding to
IFN-g, and like the ISG15-deficient patients, most were identified
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as a result of developing mycobacterial disease after receiving
the BCG vaccine (Bustamante et al., 2014). This is consistent
with the known role of IFN-g in controlling mycobacterial infec-
tions. Revisiting the earlier reports of the cytokine-like activity
of ISG15 (D’Cunha et al., 1996; Knight and Cordova, 1991), the
extracellular signaling function of ISG15 was confirmed by
showing that the BCG vaccine strain induced IFN-g production
from normal blood leukocytes cells, but not from samples
derived from the ISG15-deficient patients (Bogunovic et al.,
2012). Further, interleukin-12 (IL-12) and ISG15, added in puri-
fied form to culture media, were synergistic in stimulating the
release of IFN-g from natural killer (NK) cells and, to a lesser
extent, T cells (Bogunovic et al., 2012). A biochemical approach
identified the cell surface receptor for extracellular ISG15 as the
LFA-1 integrin (CD11a/CD18, aL/b2 integrin) (Swaim et al.,
2017). The best-characterized ligands of LFA-1 are ICAMs (intra-
cellular adhesion molecules), and ‘‘inside-out’’ signaling is
required to alter the conformation of the extracellular domains
of LFA-1 subunits in order to engage ICAMs (Luo et al., 2007;
Springer and Dustin, 2012). The aI domain of the aL/CD11a sub-
unit directly binds to ICAMs in this ‘‘open’’ or extended form of
the integrin (Shimaoka et al., 2003). Interestingly, ISG15 also in-
teracts directly with the CD11a aI domain but engages the re-
ceptor in the absence of inside-out signals, suggesting that
ISG15 binds to the closed form of LFA-1 and signals outside in
(Swaim et al., 2017). Downstream of LFA-1, it was shown that
Src family kinases (SFKs) are critical for mediating the ISG15-
dependent stimulation of IFN-g secretion by NK cells. A pro-
posed basis for synergism with IL-12 was that IL-12 induces
transcriptional activation of the IFN-g gene, while ISG15 acts
post-transcriptionally, potentially at the level of cytokine-con-
taining secretory vesicles, to promote SFK-dependent IFN-g
secretion. The effects of ISG15 on cytokine secretion are not
limited to IFN-g, because IL-12 and ISG15 were also found to
be synergistic in stimulating secretion of IL-10 (Swaim et al.,
2017), and secretion of several other cytokines was recently re-
ported to be induced by ISG15, including IL-1, IL-6, and tumor
necrosis factor (TNF) (Østvik et al., 2020).
Although the identification of LFA-1 as the ISG15 receptor re-
vealed the basis of ISG15 signaling, several important problems
remain, including the identification of the cell types and immuno-
logic signals that are capable of leading to the appearance of
ISG15 in the extracellular space. We show here that ISG15 can
be released as a soluble cytokine from both epithelial cells and
lymphocytes, and that ISG15 autocrine signaling can drive IFN-
g production from NK and T cells. Determinants of ISG15 were
identified that are required specifically for secretion of ISG15,
and intracellular ISGylation was shown to inhibit ISG15 secretion
and signaling. The NS1B protein, previously reported to bind to
ISG15 (Yuan and Krug, 2001; Zhao et al., 2016), blocked ISG15
secretion, suggesting that NS1Bmay function, in part, by inhibit-
ing antiviral IFN-g responses. In contrast, viral de-ISGylases
(vDIGs) were found to reverse intracellular ISGylation at the
cost of enhanced extracellular ISG15 secretion, suggesting that
ISG15 signaling might account, in part, for strong pro-inflamma-
tory responses and cytokine release syndrome (‘‘cytokine
storms’’) associated with infections with vDIG-expressing vi-
ruses, including coronaviruses, Nairoviruses, and FMDV.
RESULTS
A Cell-Based Reporter of ISG15 Secretion
ISG15 has been directly detected in the cell culture supernatants
of various cell types (D’Cunha et al., 1996; Knight and Cordova,
1991), and we previously showed that purified ISG15 protein,
when added directly to cell culture media, induced the secretion
of IFN-g from peripheral bloodmononuclear cells (PBMCs) and T
or NK-derived cell lines (Jurkat and NK-92 cells, respectively)
(Swaim et al., 2017). We sought to bridge these lines of experi-
mentation in an assay that would reflect both release of ISG15
from cells and a biologic readout based on IFN-g secretion. Ju-
rkat cells are defective for IFN-g expression; however, it can be
ectopically expressed by transfection of an IFN-g expression
plasmid; transfected cells will then secrete IFN-g on addition of
purified ISG15 to the culture media (Swaim et al., 2017). To
determine whether Jurkat cells were also able to serve as a
source of extracellular ISG15, we co-transfected cells with plas-
mids expressing IFN-g and ISG15. If ectopically expressed
ISG15 was secreted by the Jurkat cells, it would be predicted
to result in autocrine-like signaling via LFA-1, which would in
turn stimulate secretion of the ectopically expressed IFN-g. As
shown in Figure 1A, there was a low level of IFN-g secretion
when cells were transfected with only the IFN-g-expressing
plasmid, while co-transfection with the WT ISG15-expressing
plasmid enhanced IFN-g secretion approximately 2.5-fold. Co-
expression of IFN-g with a variant of ISG15 (Y96L/Q102D) that
cannot engage the cell surface receptor for ISG15 (LFA-1) did
not induce IFN-g secretion above background. These results
suggest that expression of ISG15 in Jurkat cells is sufficient for
secretion of ISG15, which can then signal in an autocrine manner
to induce IFN-g secretion.
To determine whether expression of ISG15 in an epithelial cell
type leads to extracellular signaling, ISG15 was expressed
ectopically in HEK293T cells in a transwell culture system, with
transfected HEK293T cells separated by a 0.4-mm membrane
from NK-92 cells in suspension. As shown diagrammatically in
Figure 1B, if diffusible extracellular ISG15 was produced by the
HEK293T cells, it would be expected to cross the barrier and
signal to the NK-92 cells. The use of the transwell system pre-
vented the potential for direct cell-cell signaling events, as well
as potential killing of the HEK293T cells by the NK-92 cells. As
shown in Figure 1C, in the absence of IL-12 andwithout transfec-
tion of the HEK293T cells, there was almost no detectable IFN-g
produced by the NK-92 cells. In the presence of IL-12 alone,
there was a modest level of IFN-g secretion, and this was signif-
icantly enhanced when the HEK293T cells were transfected with
the WT ISG15-expressing plasmid. There was no stimulation of
IFN-g secretion when the HEK293T cells were transfected with
the plasmid expressing the Y96L/Q102D ISG15 variant. These
results indicate that an epithelial cell is able to release ISG15
into the extracellular space, which can then signal to an LFA-1-
expressing cell type (e.g., NK-92 cells).
Determinants of ISG15 Required for Release from Cells
We used the HEK293T/NK-92 transwell assay to map determi-
nants of ISG15 required for secretion of ISG15. A set of surface
residue variants of ISG15 was created previously and used to




map the residues necessary for interacting with LFA-1 (Swaim
et al., 2017). A subset was expressed by transfection in
HEK293T cells in order to identify variants specifically defective
for secretion of ISG15. Variants of interest would be defective
for signaling to NK-92 cells in the transwell system (Figure 2A)
but active for signaling when added as purified proteins directly
to IL-12-stimulated NK-92 cells (Figure 2B). Three variants met
these criteria: L72A, S83A, and L85F (red bars in Figures 2A
and 2B). Although these variants appeared to signal slightly
less than WT ISG15 when added to NK-92 cells as purified pro-
teins (Figure 2B), the differences relative to WT ISG15 were not
statistically significant for the L72A or S83A variants and only
weakly significant for the L85F variant. All three secretion-def-
ection variants retained the ability to be conjugated intracellu-
larly (Figure S1A). To directly compare their expression and
secretion with wild-type (WT) ISG15, they were expressed by
transfection in HEK293T cells and detected by immunoblotting
of total cell extracts (to detect intracellular ISG15) and by
immunoprecipitation and immunoblotting of the cell culture su-
pernatants from transfected cells (to detect extracellular
ISG15). As shown in Figure 2C, all of the proteins were ex-
pressed at similar levels intracellularly, but only the WT ISG15
was detected in the cell culture supernatant. Note that ISG15
proteins expressed intracellularly remained unconjugated,
because the cells do not express the conjugating enzymes un-
der these conditions (see Figure S1A). Together, these results
indicate that L72A, S83A, and L85F variants are defective for
secretion, yet they are competent for receptor binding and for
intracellular ISGylation.
The L72, S83, and L85 residues lay on a surface that spans
the linker between the N- and C-lobe Ubl domains of ISG15
(Figure 2D). As shown in Table S1 (top), L72 and L85 in human
ISG15 are invariant across 22 other primate ISG15 sequences
examined, whereas S83 was conserved in 18 of 22 sequences.
Across 107 non-primate mammalian ISG15 sequences exam-
ined (Table S1, bottom), L85 was again invariant, whereas
L72 and S83 were conserved in 103 and 82 of these se-
quences, respectively. L72, S83, and L85 are outside of the re-
gion critical for binding to the aI domain of CD11a/aL, consis-
tent with the fact that alteration of these residues did not impair
IFN-g secretion when the proteins were added directly to NK-
92 cell culture media (Figure 2B). It should also be noted that
the Y96L/Q102D variant, defective for LFA-1 binding (and
used as a negative control in Figure 1A), was secreted similarly
to WT ISG15 (Figure S1B). A feature of the linker region of
ISG15 is a highly conserved cysteine residue; however, alter-
ation of this residue (C78S) did not affect secretion or signaling
in the transwell assay. We note it was reported that two cyste-
ines of mouse ISG15 (the linker cysteine and C144) were
required for an IFN-g response to Toxoplasma gondii infection;
however, that study reported only the effect of simultaneous
alteration of both residues, and C144 is not conserved in
Figure 1. ISG15 Is Secreted from Jurkat and HEK293T Cells
(A) Jurkat cells were transfected with cDNAs encoding IFNG and/or ISG15 or
ISG15 Y96L/Q102D. Cell culture supernatants were collected 48 h post-
transfection, and IFN-g was detected by ELISA.
(B) The transwell system for monitoring ISG15 secretion and signaling. ISG15
is expressed by transfection of HEK293T cells (lower chamber); secreted
ISG15 will cross the 0.4-mm membrane and signal to NK-92 cells (upper
chamber). Upper chamber culture supernatants are collected 48 h post-
transfection and assayed for IFN-g by ELISA.
(C) Lower chamber HEK293T cells were transfected as indicated with ISG15 or
Y96L/Q102D-expressing plasmids, with NK-92 cells (± IL-12) in the upper
chamber. Cell culture supernatants were collected 48 h post-transfection and
assayed for IFN-g. Here and in all subsequent experiments, bars represent the
average of three experiments, and error bars represent standard error of the
mean.
Ordinary one-way ANOVA was performed between each treatment condition
and the IFNG alone (A) or IL-12 alone (C). *p = 0.01, **p = 0.001, ***p = 0.0001,
****p < 0.0001. ns, non-significant changes.




Figure 2. Determinants Required for ISG15 Secretion
(A) FLAG-tagged ISG15 variants were transfected into HEK293T cells in the lower level of a transwell plate, with NK-92 cells in the upper chamber (± IL-12, as
indicated), and secreted IFN-g was measured by ELISA. L72A, S83A, and L85F (red bars) were deficient in inducing IFN-g secretion from the NK-92 cells.
Ordinary one-way ANOVA was performed between each treatment condition and the IL-12 alone condition. *p = 0.01, **p = 0.001, ***p = 0.0001, ****p < 0.0001.
ns, non-significant changes.
(B) Purified ISG15 protein and the indicated ISG15 variants were added directly to the cell culture media of NK-92 cells (± IL-12), and IFN-g secretion was
monitored by ELISA. ISG15 variants L72A, S83A, and L85F (red bars) and wild-type (WT) ISG15 stimulated IFN-g secretion, whereas the Y96L/Q102D (LFA-1
binding mutant) did not.
(legend continued on next page)




human ISG15 (Napolitano et al., 2018). Together, the results
presented here identify determinants of ISG15 required
for secretion that are separable from those required for
LFA-1 receptor interactions, and both of these sets of determi-
nants are separable from those required for intracellular
conjugation.
Bacterial Pathogens and PAMPs (Pathogen-Associated
Molecular Patterns) Stimulate the Production of
Extracellular ISG15
To identify biological factors that lead to the synthesis and secre-
tion of extracellular ISG15, we treated human PBMCs with live
(C) HEK293T cells were transfected with FLAG-tagged WT ISG15 or the indicated variant. Cell culture supernatants were monitored by anti-FLAG immuno-
precipitation and immunoblotting with anti-FLAG antibody. Only WT FLAG-ISG15 was detected in the supernatant of transfected cells. See Figure S1 for un-
cropped blots.
(D) Space-filling and backbone structures of ISG15 (PDB: 1Z2M) showing the residues required for binding to LFA-1 in blue and the residues required for ISG15
secretion in red.
Figure 3. Microbial Pathogens Stimulate
ISG15-Dependent IFN-g Secretion from
Multiple Cell Types
(A) Human PBMCs were treated with recombinant
ISG15, live BCG, heat-killed M. tuberculosis, or
heat-killed S. typhimurium, ± IL-12 as indicated.
Where indicated, anti-ISG15 antibody (I) or control
IgG antibody (C) was added to the cell culture
media. IFN-g secretion was measured by IFN-g
ELISA.
(B) Primary NK and T cells were isolated from hu-
man blood and treated with heat-killed
M. tuberculosis ± IL-12 and anti-ISG15 (I) or con-
trol antibody (C), as indicated. IFN-g secretion was
measured by ELISA.
(C) Splenocytes from control C57B6, ISG15/,
and CD11a/ mice were treated with heat-killed
M. tuberculosis or heat-killed S. typhimurium ± IL-
12. IFN-g secretion was monitored by ELISA.
Mycobacterium bovis BCG, heat-killed
Mycobacterium tuberculosis, or heat-
killed Salmonella typhimurium, in the
absence or presence of purified IL-12.
As shown in Figure 3A, none of these
agents, by themselves, elicited significant
IFN-g production, but all were synergistic
with IL-12 in stimulating production of
IFN-g production. The magnitude of
IFN-g release and degree of synergism
with IL-12 was similar to that seen when
purified ISG15 was added directly to the
culture medium (blue bars in Figure 3A).
An anti-ISG15 antibody added to the
culture medium greatly reduced IFN-g
production by the bacterial pathogens,
indicating that IFN-g production was
dependent on production and secretion
of ISG15 from one or more cell types
within the PMBC population. Primary human NK and T cells re-
sponded similarly to IL-12 and heat-killed M. tuberculosis (Fig-
ure 3B), although the absolute amount was significantly greater
with NK cells than T cells, consistent with previous results (Bogu-
novic et al., 2012). Addition of anti-ISG15 antibody to the culture
media inhibited IFN-g production, indicating that both NK and
T cells can express, secrete, and respond to extracellular
ISG15. NK-92 cells were also able to produce extracellular
ISG15 in response to IL-12 and live BCG, heat-killed
M. tuberculosis, or heat-killed S. typhimurium (Figure S2A).
To confirm that IFN-g production in response to bacterial
pathogens was dependent on ISG15 and LFA-1, we




isolated primary splenocytes from control C57B6 mice or
ISG15-deficient (ISG15/) or LFA-1-deficient mice (CD11a/).
As shown in Figure 3C, splenocytes from WT mice responded
to heat-killed M. tuberculosis and S. typhimurium similarly to
human PBMCs, producing IFN-g in synergy with IL-12. Both
the ISG15/ and CD11a/ splenocytes showed no pro-
duction of IFN-g above the level seen in either untreated sple-
nocytes or splenocytes treated only with IL-12. It should be
Figure 4. TLR Agonists and IFN-b Stimulate
ISG15-Dependent IFN-g Secretion from
Multiple Cell Types
(A) PBMCs (±IL-12) were treated with Pam3CSK4
or poly(I:C) in the presence and absence of anti-
ISG15 antibody (I) or control IgG (C). IFN-g
secretion was monitored by ELISA.
(B) Mouse splenocytes from control C57B6,
ISG15/, and CD11a/ mice were treated with
Pam3CSK4 or poly(I:C) as indicated. IFN-g
secretion was monitored by ELISA.
(C) Primary NK cells and NK-92 cells
were treated with IFN-b in the presence
and absence of anti-ISG15 antibody (I) or control
antibody (C). IFN-g was monitored by ELISA.
noted that ISG15 null mice have a
normal distribution of immune cells,
and that free ISG15 (Osiak et al., 2005),
when added to ISG15 null mouse sple-
nocytes with IL-12, elicited IFN-g re-
sponses similar to that of WT mice (Fig-
ure S2B). These results confirm that both
ISG15 and its cell-surface receptor, LFA-
1, are essential for a robust IFN-g
response to heat-killed M. tuberculosis
and S. typhimurium.
Poly(I:C), a TRL3 agonist, and
Pam3CSK4,abacterial lipoproteinmimetic
and TLR1/TLR2 agonist, were both syner-
gistic with IL-12 in inducing IFN-g produc-
tion from PBMCs (Figure 4A). Mouse sple-
nocytes from control and ISG15/ and
LFA-1/ mice were also assayed for
IFN-g production in response to these
PAMPs (Figure 4B). Control splenocytes
showed a robust response to both
PAMPs in the presence of IL-12, whereas
the response from the ISG15/ and
CD11a/ splenocytes was significantly
reduced relative to the WT splenocytes
but slightly above the level seen with IL-
12 alone. Directly treating primary NK
cells or NK-92 cells with IFN-b also led
to IFN-g production, and this was blocked
by the anti-ISG15 antibody (Figure 4C).
This is consistent with IFN-b driving
expression of both the IFNG and ISG15
genes in NK cells, as shown previously
for the IFNG gene (Mack et al., 2011; Miyagi et al., 2007).
Together, these results indicate that ISG15 acts as a secreted
cytokine that bridges pathogen recognition to type II IFN
responses.
Multiple Routes to Induction of ISG15
ISG15 is primarily induced by type I IFNs; however, there are
reports of type I IFN-independent induction of ISG15,




including by M. tuberculosis (Kimmey et al., 2017; Manzanillo
et al., 2012). Therefore, we examined mouse splenocytes
from mice deficient for the type I interferon receptor
(IFNAR1/) for IFN-g production in response to poly(I:C),
PAM3CSK4, and heat-killed S. typhimurium and M. tubercu-
losis (Figure 5A). Control splenocytes responded to all of
these agonists to produce IFN-g. The IFNAR-deficient mice
did not respond to poly(I:C) or heat-killed S. typhimurium,
but retained the response to PAM3CSK4 and heat-killed
M. tuberculosis. These results indicate that ISG15-dependent
signaling can be triggered by mechanisms independent of
type I IFN signaling. This was further confirmed with NK-92
cells using the Vaccinia B18R protein, a type I IFN binding
protein that blocks IFNAR signaling. As shown in Figure S3,
Figure 5. ISG15 Signaling Is Triggered by
Both IFN-b-Dependent and -Independent
Mechanisms
(A) Splenocytes from WT C57B6 and IFNAR/
mice were treated with the indicated TLR agonists
or heat-killed bacteria, in the absence or presence
of anti-ISG15 antibody (I) or control IgG (C). IFN-g
secretion was monitored by ELISA.
(B) NK-92 cells were treated with the indicated
TLR agonists or heat-killed M. tuberculosis and
either a MYD88 inhibitor peptide (M) or control
peptide (C).
(C) PBMCs were treated with the indicated ago-
nists, and cell culture supernatants were moni-
tored for ISG15 secretion by ISG15 ELISA.
B18R added to the culture media
strongly inhibited poly(I:C) and
S. typhimurium-induced IFN-g produc-
tion from NK-92 cells, but it had no ef-
fect on PAM3CSK4 or M. tuberculosis-
induced IFN-g production.
MyD88 is an adaptor protein required
for signaling by all TLRs, with the excep-
tion of the viral TLR sensor, TLR3. To
determine whether ISG15-dependent
IFN-g production in response to
M. tuberculosis was TLR dependent,
we tested a cell-permeable MyD88 in-
hibitor peptide for its ability to block
M. tuberculosis-mediated IFN-g secre-
tion by NK-92 cells. As shown in Fig-
ure 5B, the MyD88 inhibitor blocked
the IFN-g response to both heat-killed
M. tuberculosis and PAM3CSK4, but
did not block the response to the TLR3
agonist poly(I:C). Together, these results
indicate that the ISG15-dependent
response to heat-killed M. tuberculosis
in NK-92 cells is independent of type I
IFN, yet dependent on one or more
TLRs. Figure 5C confirms that poly(I:C),
PAM3CSK4, and heat-killed S. typhimu-
rium and M. tuberculosis all led to the
production of extracellular ISG15 as determined by an ISG15
ELISA assay of cell culture supernatants from human PBMCs.
Modulation of ISG15 Secretion by ISGylation, Influenza
NS1B, and vDIGs
To address whether ISGylated proteins produced intracellularly
can reach the extracellular space, we used the HEK293T/NK-
92 transwell assay, expressing ISG15 by transfection in
HEK293T cells, with or without co-expression of the ISG15 E1
(Uba7), E2 (UbcH8), and E3 enzymes (WT Herc5 or the active-
site C994A mutant), and assaying for IFN-g release from NK-
92 cells. As shown in Figure 6A, expression of ISG15 alone led
to robust IFN-g secretion by the NK-92 cells, whereas expres-
sion of ISG15 with the conjugation enzymes resulted in levels




of IFN-g secretion seen with IL-12 alone. When WT Herc5 was
substituted with the catalytically inactive Herc5 C994 mutant,
IFN-g secretion was again similar to that seen when ISG15
was expressed alone. Figure 6B demonstrates that ISG15 conju-
gates were formed intracellularly only when ISG15 was ex-
pressed with the E1, E2, and WT Herc5 enzymes, and as ex-
pected, the level of intracellular free (unconjugated) ISG15 was
decreased when conjugation occurred. An ISG15 immunopre-
cipitation and immunoblot of the cell culture supernatants from
the same transfected cells showed that free ISG15 was not de-
tected when it was expressed with the E1/E2/E3 (WT) enzymes,
but was detected when expressed alone or with the E1/E2/E3
(C994A) enzymes. In addition, under conditions of conjugate for-
mation, there was no detection of high-molecular-weight conju-
gates appearing in the cell culture supernatant. These results
indicate that formation of intracellular ISG15 conjugates inhibits
the secretion of ISG15, most likely by decreasing the pool of free
ISG15 available for secretion, and that high-molecular-weight
conjugates are not secreted to an appreciable degree.
NS1B binds non-covalently to both free and conjugated forms
of ISG15 (Yuan and Krug, 2001; Zhao et al., 2016). One reported
function of this interaction is to prevent ISGylated forms of the
viral NP from being incorporated into oligomeric nucleocapsid
complexes and impeding viral replication (Zhao et al., 2016).
We hypothesized that an additional or alternative function of
NS1B might be to sequester free ISG15 to prevent it from being
secreted, thus inhibiting IFN-g and/or other cytokine responses.
To test this, we expressed ISG15 in the HEK293T/NK-92 trans-
well system with or without co-expression of NS1B or a variant
that does not bind ISG15 (W36A/Q37A) (Guan et al., 2011). As
shown in Figure 6C, co-transfection of HEK293T cells with
ISG15 and NS1B prevented ISG15-mediated IFN-g release
from the NK-92 cells, whereas the W36A/Q37A variant did not.
Consistent with this, Figure 6D shows that free ISG15 was not
detectable in the cell culture supernatant when co-expressed
with NS1B, but was detectable when co-expressed with the
W36A/Q37A variant. These results indicate, in addition to abro-
gating the effects of intracellular ISGylation, NS1B inhibits the
secretion and extracellular signaling function of ISG15.
Several types of viruses encode proteases that deconjugate
ISG15 and/or ubiquitin from target proteins. Considering that
intracellular ISGylation inhibited ISG15 secretion, we hypothe-
sized that vDIGs might result in increased ISG15 secretion and
signaling to NK cells. The ERVE Nairovirus encodes an OTU
domain protease (vOTU) that has strong de-ISGylase activity
and low to no activity toward ubiquitin conjugates (Capodagli
et al., 2013). The picornavirus FMDV Lbpro protease hydrolyzes
ISG15 conjugates with high specificity relative to ubiquitin conju-
gates (Swatek et al., 2018). Lbpro is unique in that it does not hy-
drolyze the isopeptide bond formed at the ε-amino group of an
ISGylated lysine residue, but rather cleaves the peptide bond
proximal to the last two residues (Gly-Gly) of ISG15, liberating
Figure 6. ISGylation and Influenza B NS1
Inhibit ISG15 Secretion
(A) HEK293T cells were transfected in transwell
plates with plasmids expressing FLAG-ISG15,
ISG15 E1 and E2 enzymes, and Herc5 (WT or C-to-
A mutant), as indicated. NK-92 cells were in the
upper chamber, ± IL-12, as indicated. Cell culture
supernatants were monitored for IFN-g secretion
by ELISA 48 h post-transfection.
(B) HEK293T cells were transfected with FLAG-
ISG15 with or without the ISG15 E1 and E2 en-
zymes and Herc5 (WT or CA mutant). Cell culture
supernatants and total cell lysates were collected
after 48 h. Total cell lysates (left panel) were
analyzed by immunoblot with anti-FLAG antibody;
supernatants were subjected to anti-ISG15
immunoprecipitation followed by an anti-FLAG
immunoblot (right panel).
(C) HEK293T cells were transfected in transwell
plates with plasmids expressing FLAG-ISG15 and
either WT NS1B or the W36A/Q37A mutant (M), as
indicated. Cells were co-cultured with NK-92
cells ± IL-12, as indicated, and cell culture super-
natants were monitored for IFN-g secretion by
ELISA.
(D) Western blots of HEK293T cells transfected
with FLAG-ISG15 and either WT GFP-NS1B or the
W36A/Q37A mutant (M). Total cell lysates were
analyzed by immunoblotting with anti-GFP anti-
body (top panel) to detect GFP-NS1B or anti-FLAG
antibody (middle panel) to detect FLAG-ISG15.
Cell culture supernatants were subjected to an
anti-ISG15 immunoprecipitation followed by an
anti-FLAG immunoblot to detect secreted ISG15
(lower panel).




ISG15-DGG (an ISG15 variant that was shown to be active for
secretion and signaling; Figure 2A). The severe acute respiratory
syndrome (SARS) andMiddle East respiratory syndrome (MERS)
Figure 7. Viral De-ISGylases (vDIGs)
Enhance ISG15 Secretion
(A) HEK293T cells were transfected in transwell
plates with plasmids expressing FLAG-ISG15 with
or without the E1, E2, and E3 enzymes, and in the
absence or presence of the WT or active-site CA
mutants of the indicated TAP-tagged vDIG
(colored bars). NK-92 in the upper chamber and
cell culture supernatants were monitored for IFN-g
secretion by ELISA 48 h post-transfection.
(B) HEK293T cells were transfected as indicated
with FLAG-ISG15 and ISG15 E1, E2, and E3
plasmids, and WT or CA NTAP-vDIGs. Total cell
lysates were analyzed by immunoblotting with
anti-FLAG (top panel) to detect FLAG-ISG15 or
anti-TAP (two lower panels) to detect the vDIGs.
Cell culture supernatants were subjected to an
anti-FLAG immunoprecipitation followed by an
anti-FLAG immunoblot to detect secreted ISG15
(second panel from the top).
coronaviruses encode a papain-like pro-
tease (PLpro) that has a strong preference
for ISG15 over ubiquitin (Báez-Santos
et al., 2014; Daczkowski et al., 2017),
and the recently discovered SARS-CoV-
2 PLpro enzyme is 83% identical and
90% similar to SARS PLpro. The ability of
the EREV vOTU, FMDV Lbpro, and
SARS-CoV-2 PLpro proteases to enhance
ISG15 secretion when co-expressed with
the ISGylating enzymes was tested in the
HEK293T/NK-92 transwell system. As
shown in Figure 7A, expression of each
of the vDIGs restored ISG15-dependent
IFN-g secretion by NK-92 cells that was
otherwise inhibited by expression of the
ISGylating enzymes. All of these vDIGs
are cysteine proteases, and the C-to-A
active-site mutants of the enzymes
(vOTU C43A, LBpro C51A, and PLpro
C110A) were unable to restore extracel-
lular ISG15 signaling. Figure 7B shows
an immunoblot of cell lysates for intracel-
lular ISG15 with and without co-expres-
sion of the vDIGs and vDIG C-A mutants,
as well an immunoprecipitation/immuno-
blot for secreted ISG15. Consistent with
the IFN-g ELISA results, each of the
vDIGs reversed intracellular conjugates
and led to restoration of detection of
extracellular ISG15, whereas the C-A mu-
tants did not. Together, these results indi-
cate that the vDIGs tested here counter
the intracellular conjugation function but
enhance, rather than inhibit, the extracellular signaling function
of ISG15. The latter suggests that vDIG-expressing viruses are
either relatively insensitive to the downstream effects of ISG15




extracellular signaling, or that they have alternative mechanisms
for limiting cytokine responses. In addition, it is possible that
ISG15-induced pro-inflammatory cytokine production, although
predicted to be anti-viral, may be partially responsible for cyto-
kine release syndrome (‘‘cytokine storms’’), which mediates
many of the harmful effects of viral infection.
DISCUSSION
Human and murine ISG15 share two separable biochemical
functions as Ubl modifiers and as extracellular signaling pro-
teins. Human ISG15 has an additional intracellular function un-
related to conjugation, in which it regulates the stability of
Usp18, which in turn regulates signaling through the type I
IFN receptor, independently of its catalytic activity (Bogunovic
et al., 2012; Meuwissen et al., 2016; Speer et al., 2016). A chal-
lenge is to understand how these functions are temporally
related and which function(s) are critical in response to specific
infectious agents and immune stimulants. Here, we have
focused on expression, secretion, and signaling of extracellular
ISG15 in response to pathogen components. A simple but
important advance in this study was that a cell-based biological
readout of ISG15 secretion was utilized (e.g., LFA-1-dependent
IFN-g release from primary NK cells or the NK-92 cell line) rather
than relying solely on detection of ISG15 in the extracellular
space. The biological readout ensured that extracellular
ISG15 was functional for initiating downstream cytokine (IFN-
g) secretion. Based on our findings, we propose that extracel-
lular ISG15 signaling to lymphocytes (primarily NK cells) bridges
early innate immune responses to type II IFN responses, and
that viral effector proteins have differential effects on this func-
tion of ISG15.
Pattern recognition receptors detect intracellular pathogens,
leading to the production and secretion of effector molecules,
including type I IFNs and IL-12. These molecules activate the
innate immune response by increasing pathogen killing and
clearance, and initiate the process of activating IFN-g-depen-
dent humoral immune responses. The IL-12/ISG15 synergy is
particularly important for mounting the immune response to
MSMD pathogens, including mycobacterial and Salmonella in-
fections (Bustamante et al., 2014). We demonstrated here that
ISG15 expression can be induced by several immune stimu-
lants, in both a type I IFN-dependent and -independent manner.
Examples of IFN-b-dependent inducers of ISG15 expression
included poly(I:C) and heat-killed Salmonella, whereas
Pam3CSK4 and heat-killed M. tuberculosis induced ISG15
expression independently of type I IFN. Thus, although ISG15
expression is not strictly dependent on type I IFN, our results
indicate that extracellular ISG15 is a critical mediator between
initial pathogen recognition and the transition to type II IFN
responses.
Intracellular ISGylation was shown to be inhibitory to extra-
cellular signaling, providing insight into the relationship be-
tween these two functions. The simplest interpretation of
this result is that ISGylation limits the pool of free ISG15 avail-
able for secretion. In a previous study, we showed that a pu-
rified ISG15 fusion protein (ISG15-BirA), which mimics an
ISG15 conjugate, could signal through LFA-1 on NK-92 cells
when added directly to the culture media (Swaim et al.,
2017). Although this indicates that ISG15 conjugates may, in
some cases, be able to productively engage LFA-1, results
shown here indicate that it is unlikely that a significant amount
of ISGylated proteins ever reaches the extracellular space.
Interestingly, it was noted previously that IFN-b stimulation
of A549 lung carcinoma cells resulted in rapid expression of
free ISG15, with an approximate 12-h lag before the appear-
ance of significant amounts of ISGylated proteins (Loeb and
Haas, 1992; Yuan and Krug, 2001). This lag in conjugate
accumulation correlates with the delay in expression of
Uba7, UbcH8, and Herc5, relative to ISG15, in IFN-b-treated
cells (Dastur et al., 2006). It is therefore conceivable that a
delay in conjugation allows free unconjugated ISG15 to be
secreted at early time points after IFN-b stimulation, essen-
tially jump-starting secretion of IFN-g before secretion is
diminished by intracellular ISGylation. Further temporal regu-
lation of the ISG15 system by expression of the type I IFN-
induced cellular deconjugase (human Usp18/mouse Ubp43),
as well the role of free intracellular ISG15 in downregulating
signaling at the type I IFN receptor in human cells, remains
to be explored.
We have shown that ISG15 is secreted from both lympho-
cytes and epithelial cells, suggesting that the ISG15 secretion
mechanism is operational in a wide range of cell types.
Several observations suggest that ISG15 secretion is non-
conventional (i.e., not dependent on endoplasmic reticulum
[ER] transit): it does not have a signal peptide sequence,
and the fact that cytosolic viral de-ISGylating enzymes
enhanced secretion indicates that the source of secreted
ISG15 was not a pool of ISG15 that was translated into the
ER. Importantly, it is unlikely that ISG15 is being released sim-
ply by a cell death or lysis, because ISG15 autocrine signaling
was demonstrated in lymphocytes. In addition, extracellular
ISG15 signaling was inhibited by intracellular ISGylation,
despite the ability of ISGylated proteins to stimulate IFN-g
secretion from NK-92 cells when added directly to cell culture
medium (Swaim et al., 2017); if ISG15 were being released by
cell lysis, then one would expect conjugates to also appear in
the extracellular space and signal. Specific amino acid alter-
ations of ISG15 were identified that inhibited ISG15 secretion
(L72A, S83A, and L85F), and these variants may prove useful
in defining the mechanism of secretion.
The only cell types that are so far known to respond to extra-
cellular ISG15 are cells that express LFA-1, which are limited to
lymphocytes and other leukocytes. As shown previously,
engagement of LFA-1 enhances cytokine secretion, including,
but not limited to, IFN-g, dependent on Src-family kinase activity
(Swaim et al., 2017). Other cytokines that show enhanced secre-
tion in response to ISG15 include other pro-inflammatory cyto-
kines, such as CXCL1, CXCL5, IL-1, and IL-6 (Østvik et al.,
2020), as well as IL-10, an anti-inflammatory cytokine (Dos San-
tos et al., 2018; Swaim et al., 2017). It will be important to deter-
mine both the full range of immune agonists that induce ISG15
expression and secretion, and the full spectrum of cytokines
that are under the influence of extracellular ISG15.
The NS1B effector protein binds to the N-terminal Ubl domain
of ISG15 and the linker region between the Ubl domains (Guan




et al., 2011; Yuan and Krug, 2001). Interestingly, the binding of
NS1B occludes L72 of ISG15, one of the residues that are critical
for ISG15 secretion. Although it was first reported that NS1B in-
hibited ISGylation (Yuan and Krug, 2001), more recent work indi-
cates that NS1B binds and sequesters ISGylated proteins,
including the viral NP. Sequestration of ISGylated NP prevents
this pool of NP protein from being incorporated into and disrupt-
ing formation of oligomeric NP-viral RNA complexes (Zhao et al.,
2016), consistent with a model for the function of ISG15 pro-
posed earlier (Durfee et al., 2010). The results presented suggest
that influenza B is also sensitive to the extracellular functions of
ISG15, and that the NS1B protein is capable of interfering with
both of these core functions of ISG15.
Several types of animal viruses encode deubiquitinating en-
zymes (DUBs) that antagonize innate immune signaling by
reversing ubiquitination of key signaling proteins, including
RIG-I, MAVS, IKK, TBK1, and IkBa (Bailey-Elkin et al., 2017). In
some cases, these enzymes also recognize ISG15 conjugates
or have high specificity for ISG15 conjugates (Daczkowski
et al., 2017; Dzimianski et al., 2019b). Here, we analyzed en-
zymes from three viruses (the ERVE vOTU domain protease,
Lbpro from the FMDV, and PLpro from the recently described
SARS-CoV-2 coronavirus) and determined that their de-ISGyla-
tion activity reversed the inhibitory effect of intracellular ISGyla-
tion on ISG15 secretion and extracellular signaling. Highlighting
the importance of the de-ISGylating function of Lbpro, recent re-
sults indicate that defects in Lbpro de-ISGylase activity result in
decreased FMDV replication in vitro and in vivo (Medina et al.,
2020).
The SARS-CoV-2 PLpro enzyme is 83% identical to the
SARS-CoV-1 PLpro enzyme, which has been shown to have
robust de-ISGylase activity (Daczkowski et al., 2017; Lindner
et al., 2007), and the results presented here demonstrate
that SARS-CoV-2 PLpro expression also leads to deconjuga-
tion of ISG15 in cells. In addition to de-ISGylation activity,
both the FMDV and coronavirus enzymes proteolytically pro-
cess viral polyproteins, an essential function. Therefore,
small-molecule inhibitors of PLpro might have a dual therapeu-
tic effect of inhibiting cleavage of viral polyproteins and block-
ing intracellular de-ISGylation (Báez-Santos et al., 2015).
Further, the results presented here suggest inhibiting PLpro
would also limit the secretion and extracellular signaling of
ISG15. Limiting ISG15 secretion might be expected to be
detrimental in combating the infection, because pro-inflamma-
tory cytokines are important in recruiting and activating cells
of the adaptive immune response. On the other hand, if
some of the most severe and deadly consequences of infec-
tion are a result of cytokine release syndrome, then limiting
ISG15 secretion and signaling by therapeutically inhibiting
PLpro might be beneficial to coronavirus disease 2019
(COVID-19) patients.
ISG15 secretion and its relationship to IFN-g and other pro-
and anti-inflammatory cytokine responses has significant im-
plications for functional links to adaptive immune responses
and immune cell recruitment. Characterization of the sepa-
rable biochemical determinants essential for the specific func-
tions of ISG15, ISGylation, secretion, and receptor interaction,
will allow for the creation of animal models in which the spe-
cific activities of ISG15 are individually assessed and pave
the way for understanding the core functions of ISG15 in
response to specific viral and microbial pathogens, including
MSMD pathogens, influenza, and SARS-CoV-2.
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Knobeloch, K.-P., Utermöhlen, O., Kisser, A., Prinz, M., and Horak, I. (2005).
Reexamination of the role of ubiquitin-like modifier ISG15 in the phenotype
of UBP43-deficient mice. Mol. Cell. Biol. 25, 11030–11034.
Lertsooksawat, W., Wongnoppavich, A., and Chairatvit, K. (2019). Up-regula-
tion of interferon-stimulated gene 15 and its conjugation machinery, UbE1L
and UbcH8 expression by tumor necrosis factor-a through p38 MAPK and
JNK signaling pathways in human lung carcinoma. Mol. Cell. Biochem. 462,
51–59.
Lindner, H.A., Lytvyn, V., Qi, H., Lachance, P., Ziomek, E., and Ménard, R.
(2007). Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus
papain-like protease. Arch. Biochem. Biophys. 466, 8–14.
Loeb, K.R., and Haas, A.L. (1992). The interferon-inducible 15-kDa ubiquitin
homolog conjugates to intracellular proteins. J. Biol. Chem. 267, 7806–7813.
Luo, B.-H., Carman, C.V., and Springer, T.A. (2007). Structural basis of integrin
regulation and signaling. Annu. Rev. Immunol. 25, 619–647.
Mack, E.A., Kallal, L.E., Demers, D.A., and Biron, C.A. (2011). Type 1 interferon
induction of natural killer cell gamma interferon production for defense during
lymphocytic choriomeningitis virus infection. mBio 2, e00169-11.
Malakhov, M.P., Malakhova, O.A., Kim, K.I., Ritchie, K.J., and Zhang, D.-E.
(2002). UBP43 (USP18) specifically removes ISG15 from conjugated proteins.
J. Biol. Chem. 277, 9976–9981.
Manzanillo, P.S., Shiloh, M.U., Portnoy, D.A., and Cox, J.S. (2012). Mycobac-
terium tuberculosis activates the DNA-dependent cytosolic surveillance
pathway within macrophages. Cell Host Microbe 11, 469–480.
Medina, G.N., Azzinaro, P., Ramirez-Medina, E., Gutkoska, J., Fang, Y., Diaz-
San Segundo, F., and de Los Santos, T. (2020). Impairment of the deISGylation
activity of FMDV Lpro causes attenuation in vitro and in vivo. J. Virol. Published
online April 15, 2020. https://doi.org/10.1128/JVI.00341-20.
Meuwissen, M.E.C., Schot, R., Buta, S., Oudesluijs, G., Tinschert, S., Speer,
S.D., Li, Z., van Unen, L., Heijsman, D., Goldmann, T., et al. (2016). Human
USP18 deficiency underlies type 1 interferonopathy leading to severe
pseudo-TORCH syndrome. J. Exp. Med. 213, 1163–1174.
Mielech, A.M., Kilianski, A., Baez-Santos, Y.M., Mesecar, A.D., and Baker,
S.C. (2014). MERS-CoV papain-like protease has deISGylating and deubiqui-
tinating activities. Virology 450–451, 64–70.
Miyagi, T., Gil, M.P., Wang, X., Louten, J., Chu, W.-M., and Biron, C.A. (2007).
High basal STAT4 balanced by STAT1 induction to control type 1 interferon ef-
fects in natural killer cells. J. Exp. Med. 204, 2383–2396.
Morales, D.J., and Lenschow, D.J. (2013). The antiviral activities of ISG15.
J. Mol. Biol. 425, 4995–5008.
Napolitano, A., van der Veen, A.G., Bunyan, M., Borg, A., Frith, D., Howell, S.,
Kjaer, S., Beling, A., Snijders, A.P., Knobeloch, K.-P., et al. (2018).




Cysteine-Reactive Free ISG15 Generates IL-1b-Producing CD8a+ Dendritic
Cells at the Site of Infection. J. Immunol. 201, 604–614.
Narasimhan, J., Wang, M., Fu, Z., Klein, J.M., Haas, A.L., and Kim, J.-J.P.
(2005). Crystal structure of the interferon-induced ubiquitin-like protein
ISG15. J. Biol. Chem. 280, 27356–27365.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
M2 Flag Sigma CAT#F3165; RRID:AB_439685
Anti-ISG15 monoclonal Invitrogen CAT#7H29L24; RRID:AB_2784562
Anti-ISG15 monoclonal Invitrogen CAT#2H25L4; RRID:AB_2784595
Anti-ISG15 polyclonal Sigma CAT#SAB1408653; RRID:AB_10742647
Rabbit IgG isotype control Thermo Scientific CAT#02-6102; RRID:AB_2532938
Bacterial and Virus Strains
BL21 GST-3xFLAG ISG15 and variants Swaim et al., 2017 N/A
BCG Karlson and Lessel ATCC CAT#35734
Biological Samples
Human: LRS chambers with blood We Are Blood N/A
Human: PBMC Immunospot CAT# CTL-UP1
Chemicals, Peptides, and Recombinant Proteins
Mouse IL-12 R&D Systems CAT#419-ML
Human IL-12 BD PharMingen CAT#554613
IL-2 Peprotech CAT# 200-02
IFN-b Bayer betaseron
PreScission Protease GE Healthcare CAT#27-0843-01
Isopropyl b-D-1-thiogalactopyranoside Fisher Scientific CAT#BP1755-10
Pam3CSK4 InvivoGen CAT#tlrl-pm3s-1
Heat-killed M. tuberculosis InvivoGen CAT#tlrl-hkmt-1
Poly I:C HMW InvivoGen CAT#tlrl-pic
Heat-killed S. typhimurium InvivoGen CAT#tlr-hkst2
Recombinant Viral B18R protein CF R&D Systems CAT#8185-BR-025
MYD88 inhibitor peptide Novus CAT#NBP2-29328
Critical Commercial Assays
Human IFN-g ELISA Thermo Scientific CAT#EHIFNG
Human ISG15 ELISA Aviva Biosciences OKCA02472
Mouse IFN-g ELISA Thermo Scientific CAT#EM1001
Lonza SE nucleofection Lonza CAT#V4XC-2024
Pan T cell isolation kit Miltenyi Biotec CAT#130-096-535
NK cell isolation Kit Miltenyi Biotec CAT#130-092-657
Deposited Data
Mendeley Data this paper https://doi.org/10.17632/4fvk98cr38.1
Experimental Models: Cell Lines
Human: NK-92 cells ATCC CAT#CRL-2407
Human: Jurkat cells ATCC CAT#TIB-152
Human: HEK293T cells ATCC CAT#CRL-3216
Experimental Models: Organisms/Strains
Mouse: C57B6 spleens Jackson Laboratory CAT#JR 644
Mouse: C57B6 CD11a/ spleens Jackson Laboratory CAT#JR 5257
Mouse: C57B6 ISG15/ spleens Osiak et al., 2005 K.-P. Knobelach
Mouse: C57B6 IFNAR1/ spleens Jackson Laboratory CAT#JR 644
(Continued on next page)






Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Jon
Huibregtse (huibregtse@austin.utexas.edu)
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant DNA
pGEM-T IFNG Sino Biological CAT#HG11725-G
pcDNA3 UBE1L Durfee et al., 2008 N/A
pcDNA3 UBCH8 Durfee et al., 2008 N/A
pcDNA3 HA HERC5 Durfee et al., 2008 N/A
pcDNA3 HA HERC5 C994A Durfee et al., 2008 N/A
pcDNA3 3xFLAG-ISG15 Swaim et al., 2017 N/A
pcDNA3 3xFLAG-ISG15 Y96L Q102D Swaim et al., 2017 N/A
pcDNA3 3xFLAG-ISG15 W3F This paper N/A
pcDNA3 3xFLAG-ISG15 M9T This paper N/A
pcDNA3 3xFLAG-ISG15 Q34D This paper N/A
pcDNA3 3xFLAG-ISG15 I36A This paper N/A
pcDNA3 3xFLAG-ISG15 F41D This paper N/A
pcDNA3 3xFLAG-ISG15 R44A This paper N/A
pcDNA3 3xFLAG-ISG15 P67A This paper N/A
pcDNA3 3xFLAG-ISG15 T70A This paper N/A
pcDNA3 3xFLAG-ISG15 L72A This paper N/A
pcDNA3 3xFLAG-ISG15 S83A This paper N/A
pcDNA3 3xFLAG-ISG15 L85F This paper N/A
pcDNA3 3xFLAG-ISG15 K90A This paper N/A
pcDNA3 3xFLAG-ISG15 S95A This paper N/A
pcDNA3 3xFLAG-ISG15 W123A P130A This paper N/A
pcDNA3 3xFLAG-ISG15 K143A This paper N/A
pGEX-6p 3xFLAG-ISG15 L72A This paper N/A
pGEX-6p 3xFLAG-ISG15 L85F This paper N/A
pcDNA GFP NS1B 1-281 (Influenza B
virus B/Yamanashi/166/1998)
This paper N/A
pcDNA GFP NS1B 1-281 W36A Q37A
(Influenza B virus B/Yamanashi/166/1998)
This paper N/A
pcDNA NTAP ERVE vOTU This paper N/A
pcDNA NTAP ERVE vOTU C43A This paper N/A
pcDNA NTAP FMDV LBpro This paper N/A
pcDNA NTAP FMDV LBpro C51A This paper N/A
pcDNA NTAP SARS-CoV2 PLpro This paper N/A
pcDNA NTAP SARS-CoV2 PLpro C110A This paper N/A
pGEX-6p 3xFLAG-ISG15 WT Swaim et al., 2017 N/A
pGEX-6p 3xFLAG-ISG15 S83A Swaim et al., 2017 N/A
pGEX-6p 3xFLAG-ISG15 Y96L Q102D Swaim et al., 2017 N/A
Software and Algorithms
Prism 8 Graphpad N/A
Other
Sera-Mag SpeedBead Protein A/G GE Life Sciences CAT#17152104010150
Protein A Sepharose Invitrogen CAT#101141
Glutathione Sepharose GE Healthcare CAT#17075601





All newly generated reagents for this study are available at the institution of the lead contact.
Data and Code Availability
Raw western blot data uploaded to Mendeley Data at https://doi.org/10.17632/4fvk98cr38.1
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture
Human peripheral blood mononuclear cells (PBMCs) were obtained from Immunospot and donors were uncharacterized with
respect to sex or age. Primary NK and T cells were isolated from leukoreduction system chambers (LRS chambers) obtained
from We Are Blood (Austin, TX); T cells were isolated from three male donors (ages 50, 58, and 71 years) and NK cells were isolated
from two 49 year old female donors and a 57 year oldmale donor. Primary NK cells, primary T cells, HEK293T, Jurkat, andNK-92 cells
were maintained at 37C, 5% v/v CO2 in a humidified incubator. HEK293T cells were maintained in DMEM (Corning) supplemented
with 10%FBS (Sigma) and 1%Penicillin-Streptomycin (Corning). Jurkat cells were cultured in RPMI 1640 (Sigma), 10%FBS (Sigma),
1%Penicillin-Streptomycin. NK-92 cells were cultured in NKmedia; AlphaMEMwithout nucleosides (GIBCO) with 2mML-glutamine
(Fisher), 1.5 g/l sodium bicarbonate (Sigma), 0.2 mM inositol (Sigma), 0.1 mM 2-mercaptoethanol, 0.02 mM folic acid (Fisher), 100U/
ml recombinant IL-2 (Peprotech), 12.5% horse serum (GIBCO) and 12.5% FBS (Corning).
PBMC, T and NK cell isolation
PBMCs from healthy individuals were isolated from Leukoreduction System (LRS) Chambers obtained from We Are Blood (Austin,
TX). The LRS chamber blood was diluted 1:1 with PBS+2% FBS and transferred to a SepMate tube (Stem Cell Technologies)
containing an equal volume of Ficoll Plaque (GE Healthcare). The tube was centrifuged at 1,200 x g for 10 minutes at room temper-
ature. The top layer containing the enriched mononuclear cells (MNCs) was poured off to a separate tube. The enriched MNCs were
washed twicewith PBS containing 2%FBS. To eliminate any red blood cells (RBCs) present in theMNC fraction, cells were lysedwith
1X RBC lysis buffer (Biolegend). TheMNCswere then counted and either frozen in RPMI 1640 containing 20%FBS and 5%DMSO or
plated in RPMI 1640 at 1x106 cells per mL. CD3+ T cells were isolated from PBMCs by magnetic cell separation using a Pan T cell
isolation kit (Miltenyi Biotec) as per manufacturer’s protocol. CD56+ NK cells were isolated from PBMCs by magnetic cell separation
using a NK cell isolation kit (Miltenyi Biotec) as per manufacturer’s protocol. Cells were sub-cultured in RPMI 1640 with 20% human
serum (Omega Scientific) at 1x106 cells per mL.
Mouse splenocyte isolation and treatment
Spleens from four WT C57B6 (JR00664), CD11a/ (JR005357) (Ding et al., 1999), and IFNAR1/ (JR028288) (Prigge et al., 2015)
mice (twomale and two femalemice for each strain) were obtained from Jackson Laboratory. Each spleenwas placed in a 60mMdish
with 10mL PBS. ISG15/micewere described previously (Knobeloch et al., 2005). Spleens were poked with a 26-gauge needle and
crushed with the flat end of a 3 mL syringe. Cells and detritus were collected into a 15mL conical tube. Large debris settled to the
bottom and cells were transferred to a second conical tube and spun at 500 x g for 5 minutes. Cell pellets were resuspended in
RPMI 1640. Splenocytes were counted and plated in RPMI 1640 at 1x106 cells per mL and incubated overnight at 37Cwith 5%CO2.
BCG culture
Bacillus Calmette-Guérin (BCG) Karlson Lessel was obtained from ATCC and grown in Middlebrook 7H9 medium with ADC enrich-
ment at 37C with shaking. Cultures were monitored by A600 in a spectrophotometer and kept in log phase. BCG was added to
PBMC and NK-92 cultures at a concentration of 100 cfu per sample.
METHOD DETAILS
Human PBMC, NK-92, and mouse splenocyte treatments and IFN-g ELISAs
Human PBMC, NK-92 cells and mouse splenocytes were rested overnight in RPMI 1640 10%, FBS and NK media without IL2, or
RPMI 1640 at a concentration of 1x106 cells/mL. Rested cells were treated with 30ng/mL heat-killed M. tuberculosis, 106 cells/mL
heat-killed S. typhimurium, 10ng/mL Pam3CSK4, 1mg/mL poly I:C, 18 ng/mLmIL-12 or 18 ng/mL hIL-12 and 2400 ng/mL bacterially
purified ISG15 (mouse or human; prepared as described in Swaim et al., 2017) for 48 hours. Supernatants were collected and moni-
tored for IFN-g production by ELISA (Thermo Fisher). B18R 10ng/mL (R&D Systems), MYD88 inhibitor peptide or control peptide
100mM (Novus), anti-ISG15 3mg/mL (Sigma) or Control IgG 3mg/mL (Thermo-Fisher) were used as indicated.
ISG15 ELISA assays
ISG15 ELISAs were performed on PBMCs cultured in RPMI 1640 without serum (serum proteins interfere with ELISA detection of
ISG15; data not shown). 1x106 PBMCs/mL were plated for 16 hours and then treated with heat-killed M. tuberculosis, heat-killed




S. typhimurium, Pam3CSK4 or poly I:C for 48 hours. Supernatants were collected and ISG15 concentrations were measured by the
Aviva ISG15 Elisa Kit according to the recommended protocol (Aviva Biosciences).
Jurkat transfections
Jurkat cells were seeded at 5x105 cells/mL two days before transfection. Cells were counted and resuspended at 1x106 cells/100mL
of Lonza SE. Nucleofection reagent with 2 mg/sample of the indicated DNA. Cells were transfected with a Lonza Nucleofector 4d us-
ing program cl-120. Freshly transfected cells were rested for 3 hours in RPMI 1640 with 10% serum, then plated at a density of 1x106
cells/mL and cultured for 48 hours. Cell culture supernatants were analyzed for human IFN-g by ELISA (Thermo Fisher).
293T NK-92 transwell assay
1x105 HEK293T cells per well were seeded in the lower chamber of 24-well Corning transwell plates (0.4 mm membrane; Fisher
Scientific). At the same time, NK-92 cells (1x106 cells per ml) were transferred to media without IL-2 for 16 hours. HEK293T cells
were transfected with 100ng of plasmid expressing FLAG-ISG15 or the indicated ISG15 variant, with or without plasmids expressing
NS1B (synthesized by GenScript from Influenza B virus B/Yamanashi/166/1998 sequence), ISG15 conjugation components (Ube1L,
UbcH8, Herc5), or the indicated vDIG (ERVEV vOTU, FMDV Lbpro, SARS-CoV2 PLpro), using X-tremeGENE HP DNA transfection
reagent (Roche). 0.3 mL of NK-92 cells (at 1x106 per mL) were added to the upper chamber of the transwell chamber, with or without
IL-12 as indicated, and cultured for 48 hours. Cell culture supernatants were collected from the upper transwell chamber and assayed
for IFN-g production by IFN-g ELISA. (Thermo Scientific).
ISG15 immunoprecipitations from cell culture supernatants
HEK293T cells were seeded in 10 cmplates at 1.3x106 cells/ml in 10mLDMEMwith 10%FBS and 1%penicillin streptomycin the day
before transfection. 3mg of indicated ISG15 or mutant were transfected, using X-tremeGENE HP DNA transfection reagent (Roche),
into one 10 cm plate and grown for 48 hours. Cell culture supernatants were collected and cleared of any cell debris by centrifugation
at 1000xg. These cell culture supernatants were further cleared of IgG from the serum by two one-hour bindings with Protein A
Sepharose (Invitrogen) at room temperature. 20uL of Sera-Mag SpeedBead Protein A/G magnetic beads (GE Life Sciences),
10 uL of ISG15 antibody (Invitrogen 7H29L24) and 20 mL of 0.1% NP40 in PBS pH 7.0 were added to the cell culture supernatants
and rocked for 2 hours at room temperature. Beads were isolated with a neodymiummagnet and washed 3X with 0.1%NP40 in PBS
pH7.0. ISG15was eluted from the beads by boiling in 80ml of 1X loading dye and 40ml was run on aNuPAGE 4%–12%Bis-Tris gel and
transferred to nitrocellulose for western blotting. ISG15 was detected with the M2 Flag antibody (Sigma).
ISG15 purification
ISG15 proteins were purified as GST fusion proteins in BL21 E. coli. Overnight starter cultures were grown at 37C for 16
hours. Cultures were diluted 1:10 and cultured with shaking for 2 hours at 37C. Expression of proteins was induced with
100 mM Isopropyl b-D-1-thiogalactopyranoside (IPTG) for 3 hours at 30C. Cells were collected by centrifugation, resuspended
in 10 mL PBS with 1% Triton X-100, and sonicated for 30 s. Lysates were spun at 15,000xg for 10 minutes, and supernatants
were incubated with Glutathione Sepharose (GE Healthcare) for 2 hours with rotation at 4C. Beads were collected and
washed 3X with PBS plus 1% Triton X-100 and 3X with 50mM Tris pH 8.0, 150mM NaCl, 0.01% Triton X-100, and 2.5mM
EDTA. GST fusion proteins (on beads) were subjected to site-specific cleavage with PreScission Protease (GE Healthcare)
to remove the GST tag. Beads were removed and protein concentration in the supernatant was quantified by SDS-PAGE using
a Li-Cor Odyssey Imager.
Cloning of de-ISGylating enzymes
The SARS-CoV-2 PLpro open reading frame (corresponding to nsp3 amino acids 774-1061) was synthesized by Genscript and
cloned into pcDNA-NTAP using BamHI and NotI restriction enzymes. FMDV Lbpro plasmid was a gift from David Komander
and was subcloned into pcDNA-NTAP using BamHI and NotI restriction sites. pET11a ERVE vOTU was a gift from Scott Pe-
gan and was cloned into pcDNA NTAP using BamHI and EcoRI restriction sites. C-A mutations for SARS-CoV-PLPro and
FMDV LbPro were generated using Quikchange mutagenesis (Stratagene), while the C-A mutation for ERVE vOTU was
made using blunt end ligation.
Cytokines, inhibitors and small molecules
Cytokines used include mouse IL-12, (R&D Systems), human IL-12 (BD PharMingen), human IL-2 (Peprotech), IFN-b (Betaseron,
Bayer), B18R (R&D systems), MYD88 inhibitor peptide or control peptide (Novus), PAM3CSK4, poly I:C, heat killed
M. tuberculosis, heat killed S. typhimurium (InvivoGen).
Antibodies and bead reagents
Antibody reagents used here were anti-M2 FLAG antibody (Sigma), anti-ISG15 polyclonal (Sigma), anti-ISG15monoclonal (Invitrogen
2H25L4, 7H29L24), Protein A Sepharose (Invitrogen), Sera-Mag SpeedBead Protein A/G (GE Life Sciences).




QUANTIFICATION AND STATISTICAL ANALYSIS
Graphpad Prism 8 software was used to plot all ELISA data. Bars represent three biological replicates of technical duplicates. Error
bars are standard error of the mean (SEM). Ordinary one-way ANOVA was performed on each ELISA dataset. Asterisks indicate
p values as follows: * = 0.01, ** = 0.001, *** = 0.0001, **** < 0.0001, and non significant changes are indicated by ns.




Cell Reports, Volume 31
Supplemental Information
Modulation of Extracellular ISG15 Signaling
by Pathogens and Viral Effector Proteins
Caleb D. Swaim, Larissa A. Canadeo, Kristen J. Monte, Swati Khanna, Deborah J.
Lenschow, and Jon M. Huibregtse
Supplementary Figure Legends 
Supplementary Figure 1 related to Figure 2. Non-secreted ISG15 mutants are conjugated, 
and non-signaling mutants are secreted. A. HEK293T cells were transfected with FLAG-
ISG15 or the indicated non-secreted FLAG-tagged ISG15 variants (L72A, S83A, L85F), in the 
absence or presence of the conjugation enzymes (Ube1L, Ube2L6, and Herc5). Total cell 
extracts were analyzed by immunoblotting with anti-FLAG antibody. Molecular weight markers 
are indicated (kDa) and the position of free FLAG-ISG15 is indicated. B. The Y96L/Q102D 
ISG15 variant, which is defective for binding to LFA-1, is secreted from HEK293T cells. 
HEK293T cells were transfected with FLAG-ISG15 WT or FLAG-ISG15 Y96L/Q102D. Cell 
culture supernatants were monitored by anti-ISG15 immunoprecipitation and immunoblotting for 
extracellular FLAG-ISG15. C. Uncropped western blots corresponding to main Figure 2C. 
HEK293T cells were transfected with FLAG-tagged WT ISG15 or the L72A, S83A or L85F 
variants. Cell lysates were monitored by anti-FLAG immunoblotting for FLAG tagged ISG15 
variant (right). Cell culture supernatants were monitored by anti-ISG15 immunoprecipitation and 
immunoblotting with anti-FLAG antibody. Only WT FLAG-ISG15 was detected in the 
supernatant of transfected cells (Left).  
 
Supplementary Figure 2 related to Figure 3. Microbial pathogens stimulate ISG15-
dependent IFN-γ secretion from NK-92 cells. A. NK-92 cells were treated as indicated with 
IL-12, purified ISG15 protein, live BCG, heat killed M. tuberculosis, or heat killed S. typhimurium 
in the presence and absence of anti-ISG15 antibody (I) or control antibody (C). Cell culture 
supernatants were assayed for IFN-γ secretion by ELISA. Bars represent an average of three 
experiments and error bars are standard error of the mean. B. Splenocytes from WT and ISG15-
/- mice were treated with bacterially purified ISG15 and IL-12 for 48 hours. Cell culture 
supernatants were monitored for IFN-γ by ELISA. Ordinary one-way ANOVA was performed 
between each treatment condition and the IL-12 alone condition. Asterisks indicate p-values as 
follows: *=0.01, **=0.001, ***=0.0001, ****<0.0001, and non-significant changes are indicated by 
ns.  
 
Supplementary Figure 3 related to Figure 5. B18R inhibits IFN-γ production by PBMCs in 
response to poly I:C and S. typhimurium, but not Pam3SK4 or M. tuberculosis. PBMCs 
were treated as indicated with IL-12, Poly I:C, Pam3CSK4, heat killed M. tuberculosis, or heat 
killed S. typhimurium, or IFN-β and the type I interferon-binding protein B18R from vaccinia 
virus. Cell culture supernatants were assayed for IFN-γ secretion by ELISA. Bars represent an 
average of three experiments and error bars are standard error of the mean. Ordinary one-way 
ANOVA was performed between each treatment condition and the IL-12 alone condition. 
Asterisks indicate p-values as follows: *=0.01, **=0.001, ***=0.0001, ****<0.0001, and non-
significant changes are indicated by ns. 
 



